BioDech
In today's competitive landscape, life sciences companies routinely face a myriad of legal complexities and regulatory issues, from early-stage financing for clinical trials and IPO preparedness, to antitrust, securities or patent disputes post-product launch. Despite the challenges, innovation in the market is more active than ever.To help companies navigate these issues, BioDech brings together life sciences industry leaders with lawyers from Dechert’s cross-practice global life sciences team to discuss the challenges and opportunities that may arise at every phase of the life sciences life cycle, from discovery through development, clinical testing, promotion and sales.
BioDech
Latest Episodes
One in Four: What Makes Life Sciences Companies So Vulnerable to Securities Class Actions
Securities class actions are on the rise and life sciences organizations are of specific interest to regulators. In our sixth episode of BioDech, a global life sciences broadcast series, Joni Jacobsen, co-chair of the global securit...
Episode 5 | Executive Compensation Considerations for a Successful IPO
Executive compensation plays a critical role in preparing for a successful IPO. In the fifth episode of BioDech, a global life sciences broadcast series, Kevin Kay, partner in Dechert's Employee Benefits and Executive Compensation practi...
Episode 4 | What Every Life Sciences Company Needs to Know About Cybersecurity
Cybersecurity is the number one topic that keeps boards and executives up at night. Threats of all kinds – from nation states to organized crime – are eager to steal the most valuable information and hold your company ransom, among other cyber ...
Episode 3 | Corporate Governance Considerations Pre-IPO
In the third episode of BioDech, a global life sciences broadcast series, Jolie Siegel, Chief Legal Officer of C4 Therapeutics, Inc., and Marco Taglietti, M.D., Independent Board Director of Aquestive Therapeutics, join Dech...